{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T23:18:28Z","timestamp":1793834308455,"version":"4.6.1"},"reference-count":91,"publisher":"American Society of Hematology","issue":"10","license":[{"start":{"date-parts":[[2024,4,2]],"date-time":"2024-04-02T00:00:00Z","timestamp":1712016000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2024,5,28]]},"abstract":"<jats:sec>\n                  <jats:title>Abstract<\/jats:title>\n                  <jats:p>Newer immune-based approaches based on recruitment and redirection of endogenous and\/or synthetic immunity such as chimeric antigen receptor T cells or bispecific antibodies are transforming the clinical management of multiple myeloma (MM). Contributions of the immune system to the antitumor effects of myeloma therapies are also increasingly appreciated. Clinical malignancy in MM originates in the setting of systemic immune alterations that begin early in myelomagenesis and regional changes in immunity affected by spatial contexture. Preexisting and therapy-induced changes in immune cells correlate with outcomes in patients with MM including after immune therapies. Here, we discuss insights from and limitations of available data about immune status and outcomes after immune therapies in patients with MM. Preexisting variation in systemic and\/or regional immunity is emerging as a major determinant of the efficacy of current immune therapies as well as vaccines. However, MM is a multifocal malignancy. As with solid tumors, integrating spatial aspects of the tumor and consideration of immune targets with the biology of immune cells may be critical to optimizing the application of immune therapy, including T-cell redirection, in MM. We propose 5 distinct spatial immune types of MM that may provide an initial framework for the optimal application of specific immune therapies in MM: immune depleted, immune permissive, immune excluded, immune suppressed, and immune resistant. Such considerations may also help optimize rational patient selection for emerging immune therapies to improve outcomes.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1182\/bloodadvances.2023011242","type":"journal-article","created":{"date-parts":[[2024,4,2]],"date-time":"2024-04-02T20:58:25Z","timestamp":1712091505000},"page":"2424-2432","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":19,"title":["Immune status and selection of patients for immunotherapy in myeloma: a proposal"],"prefix":"10.1182","volume":"8","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8249-5988","authenticated-orcid":false,"given":"Madhav V.","family":"Dhodapkar","sequence":"first","affiliation":[{"name":"Department of Hematology and Oncology, Winship Cancer Institute, Emory University, Atlanta, GA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2024,5,20]]},"reference":[{"key":"2024052418405094400_bib1","doi-asserted-by":"crossref","first-page":"17046","DOI":"10.1038\/nrdp.2017.46","article-title":"Multiple myeloma","volume":"3","author":"Kumar","year":"2017","journal-title":"Nat Rev Dis Prim"},{"issue":"7","key":"2024052418405094400_bib2","doi-asserted-by":"crossref","first-page":"1541","DOI":"10.1158\/1078-0432.CCR-19-2111","article-title":"How to train your T cells: overcoming immune dysfunction in multiple myeloma","volume":"26","author":"Cohen","year":"2020","journal-title":"Clin Cancer Res"},{"issue":"8","key":"2024052418405094400_bib3","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1056\/NEJMoa2024850","article-title":"Idecabtagene vicleucel in relapsed and refractory multiple myeloma","volume":"384","author":"Munshi","year":"2021","journal-title":"N\u00a0Engl J Med"},{"issue":"10297","key":"2024052418405094400_bib4","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1016\/S0140-6736(21)00933-8","article-title":"Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b\/2 open-label study","volume":"398","author":"Berdeja","year":"2021","journal-title":"Lancet"},{"issue":"6","key":"2024052418405094400_bib5","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1056\/NEJMoa2203478","article-title":"Teclistamab in relapsed or refractory multiple myeloma","volume":"387","author":"Moreau","year":"2022","journal-title":"N\u00a0Engl J Med"},{"issue":"9","key":"2024052418405094400_bib6","doi-asserted-by":"crossref","first-page":"2259","DOI":"10.1038\/s41591-023-02528-9","article-title":"Elranatamab in relapsed or refractory multiple myeloma: phase 2 MagnetisMM-3 trial results","volume":"29","author":"Lesokhin","year":"2023","journal-title":"Nat Med"},{"issue":"6","key":"2024052418405094400_bib7","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1016\/j.clml.2023.03.009","article-title":"Immune reconstitution and vaccinations in multiple myeloma: a report from the 19th International Myeloma Society Annual Workshop","volume":"23","author":"Terpos","year":"2023","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"670","key":"2024052418405094400_bib8","doi-asserted-by":"crossref","first-page":"eadf2947","DOI":"10.1126\/scitranslmed.adf2947","article-title":"Immune checkpoint therapy: forging ahead","volume":"14","author":"Sharma","year":"2022","journal-title":"Sci Transl Med"},{"issue":"328","key":"2024052418405094400_bib9","doi-asserted-by":"crossref","first-page":"328rv4","DOI":"10.1126\/scitranslmed.aad7118","article-title":"PD-L1 (B7-H1) and PD-1 pathway blockade for cancer therapy: mechanisms, response biomarkers, and combinations","volume":"8","author":"Zou","year":"2016","journal-title":"Sci Transl Med"},{"issue":"23","key":"2024052418405094400_bib10","doi-asserted-by":"crossref","first-page":"2698","DOI":"10.1200\/JCO.2015.65.9789","article-title":"Nivolumab in patients with relapsed or refractory hematologic malignancy: preliminary results of a phase Ib study","volume":"34","author":"Lesokhin","year":"2016","journal-title":"J\u00a0Clin Oncol"},{"issue":"16","key":"2024052418405094400_bib11","doi-asserted-by":"crossref","first-page":"1689","DOI":"10.1182\/blood-2018-01-825265","article-title":"TIGIT immune checkpoint blockade restores CD8(+) T-cell immunity against multiple myeloma","volume":"132","author":"Guillerey","year":"2018","journal-title":"Blood"},{"issue":"1","key":"2024052418405094400_bib12","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1186\/s40425-014-0043-z","article-title":"Combined immune checkpoint protein blockade and low dose whole body irradiation as immunotherapy for myeloma","volume":"3","author":"Jing","year":"2015","journal-title":"J\u00a0Immunother Cancer"},{"issue":"20","key":"2024052418405094400_bib13","doi-asserted-by":"crossref","first-page":"13009","DOI":"10.1073\/pnas.202491499","article-title":"T\u00a0cells from the tumor microenvironment of patients with progressive myeloma can generate strong tumor specific cytolytic responses to autologous tumor loaded dendritic cells","volume":"99","author":"Dhodapkar","year":"2002","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"12","key":"2024052418405094400_bib14","doi-asserted-by":"crossref","first-page":"1667","DOI":"10.1084\/jem.20021650","article-title":"A\u00a0reversible defect in natural killer T cell function characterizes the progression of premalignant to malignant multiple myeloma","volume":"197","author":"Dhodapkar","year":"2003","journal-title":"J\u00a0Exp Med"},{"issue":"23","key":"2024052418405094400_bib15","doi-asserted-by":"crossref","first-page":"2599","DOI":"10.1182\/blood-2016-09-692954","article-title":"MGUS to myeloma: a mysterious gammopathy of underexplored significance","volume":"128","author":"Dhodapkar","year":"2016","journal-title":"Blood"},{"issue":"11","key":"2024052418405094400_bib16","doi-asserted-by":"crossref","first-page":"1753","DOI":"10.1084\/jem.20031030","article-title":"Vigorous premalignancy-specific effector T cell response in the bone marrow of patients with monoclonal gammopathy","volume":"198","author":"Dhodapkar","year":"2003","journal-title":"J\u00a0Exp Med"},{"issue":"4","key":"2024052418405094400_bib17","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1084\/jem.20062387","article-title":"Frequent and specific immunity to the embryonal stem cell-associated antigen SOX2 in patients with monoclonal gammopathy","volume":"204","author":"Spisek","year":"2007","journal-title":"J\u00a0Exp Med"},{"issue":"11","key":"2024052418405094400_bib18","doi-asserted-by":"crossref","first-page":"e127807","DOI":"10.1172\/jci.insight.127807","article-title":"Early alterations in stem-like\/resident T cells, innate and myeloid cells in the bone marrow in preneoplastic gammopathy","volume":"5","author":"Bailur","year":"2019","journal-title":"JCI Insight"},{"issue":"5","key":"2024052418405094400_bib19","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1038\/s43018-020-0053-3","article-title":"Single-cell RNA sequencing reveals compromised immune microenvironment in precursor stages of multiple myeloma","volume":"1","author":"Zavidij","year":"2020","journal-title":"Nat Cancer"},{"issue":"6","key":"2024052418405094400_bib20","doi-asserted-by":"crossref","first-page":"eaai8593","DOI":"10.1126\/sciimmunol.aai8593","article-title":"The TCF1-Bcl6 axis counteracts type I interferon to repress exhaustion and maintain T cell stemness","volume":"1","author":"Wu","year":"2016","journal-title":"Sci Immunol"},{"issue":"1","key":"2024052418405094400_bib21","doi-asserted-by":"crossref","first-page":"5825","DOI":"10.1038\/s41467-023-41562-6","article-title":"Large T cell clones expressing immune checkpoints increase during multiple myeloma evolution and predict treatment resistance","volume":"14","author":"Botta","year":"2023","journal-title":"Nat Commun"},{"issue":"6","key":"2024052418405094400_bib22","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1158\/2643-3230.BCD-22-0018","article-title":"Changes in bone marrow tumor and immune cells correlate with durability of remissions following BCMA CAR T therapy in myeloma","volume":"3","author":"Dhodapkar","year":"2022","journal-title":"Blood Cancer Discov"},{"issue":"15","key":"2024052418405094400_bib23","doi-asserted-by":"crossref","first-page":"2975","DOI":"10.1182\/blood-2012-08-448548","article-title":"Tumor-promoting immune-suppressive myeloid-derived suppressor cells in the multiple myeloma microenvironment in humans","volume":"121","author":"G\u00f6rg\u00fcn","year":"2013","journal-title":"Blood"},{"issue":"7","key":"2024052418405094400_bib24","first-page":"3815","article-title":"Myeloid-derived suppressor cells regulate growth of multiple myeloma by inhibiting T cells in","volume":"190","author":"Ramachandran","year":"2013","journal-title":"bone marrow. J Immunol"},{"issue":"1","key":"2024052418405094400_bib25","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1038\/s41525-022-00340-x","article-title":"Cross center single-cell RNA sequencing study of the immune microenvironment in rapid progressing multiple myeloma","volume":"8","author":"Pilcher","year":"2023","journal-title":"NPJ Genom Med"},{"issue":"10","key":"2024052418405094400_bib26","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1158\/2767-9764.CRC-22-0022","article-title":"Comprehensive characterization of the multiple myeloma immune microenvironment using integrated scRNA-seq, CyTOF, and CITE-seq analysis","volume":"2","author":"Yao","year":"2022","journal-title":"Cancer Res Commun"},{"issue":"7","key":"2024052418405094400_bib27","doi-asserted-by":"crossref","first-page":"1797","DOI":"10.1182\/bloodadvances.2020003857","article-title":"Microenvironment immune reconstitution patterns correlate with outcomes after autologous transplant in multiple myeloma","volume":"5","author":"Parmar","year":"2021","journal-title":"Blood Adv"},{"issue":"9","key":"2024052418405094400_bib28","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1038\/s41408-019-0234-4","article-title":"Mass cytometry dissects T cell heterogeneity in the immune tumor microenvironment of common dysproteinemias at diagnosis and after first line therapies","volume":"9","author":"Kourelis","year":"2019","journal-title":"Blood Cancer J"},{"issue":"11","key":"2024052418405094400_bib29","doi-asserted-by":"crossref","first-page":"1358","DOI":"10.1016\/j.ccell.2022.10.017","article-title":"Immune biomarkers of response to immunotherapy in patients with high-risk smoldering myeloma","volume":"40","author":"Sklavenitis-Pistofidis","year":"2022","journal-title":"Cancer Cell"},{"issue":"12","key":"2024052418405094400_bib30","doi-asserted-by":"crossref","first-page":"1660","DOI":"10.1038\/s43018-023-00657-1","article-title":"Genomic and immune signatures predict clinical outcome in newly diagnosed multiple myeloma treated with immunotherapy regimens","volume":"4","author":"Maura","year":"2023","journal-title":"Nat Cancer"},{"issue":"1","key":"2024052418405094400_bib31","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1615\/CritRevOncog.2023048380","article-title":"Role of natural killer T (NKT) cells in myeloma biology and therapy","volume":"29","author":"Dhodapkar","year":"2024","journal-title":"Crit Rev Oncog"},{"issue":"2","key":"2024052418405094400_bib32","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1016\/j.hoc.2023.12.011","article-title":"Immune-pathogenesis of myeloma","volume":"38","author":"Dhodapkar","year":"2024","journal-title":"Hematol Oncol Clin North Am"},{"issue":"Suppl 2","key":"2024052418405094400_bib33","first-page":"S4","article-title":"The immune system in multiple myeloma and precursor states: lessons and implications for immunotherapy and interception","volume":"98","author":"Dhodapkar","year":"2023","journal-title":"Am J Hematol"},{"issue":"7","key":"2024052418405094400_bib34","doi-asserted-by":"crossref","first-page":"2904","DOI":"10.1172\/JCI82646","article-title":"Immunosurveillance and therapy of multiple myeloma are CD226 dependent","volume":"125","author":"Guillerey","year":"2015","journal-title":"J\u00a0Clin Invest"},{"issue":"4","key":"2024052418405094400_bib35","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1016\/j.ccell.2018.02.007","article-title":"Dysregulated IL-18 is a key driver of immunosuppression and a possible therapeutic target in the multiple myeloma microenvironment","volume":"33","author":"Nakamura","year":"2018","journal-title":"Cancer Cell"},{"issue":"3","key":"2024052418405094400_bib36","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1038\/s41591-022-02178-3","article-title":"Preclinical models for prediction of immunotherapy outcomes and immune evasion mechanisms in genetically heterogeneous multiple myeloma","volume":"29","author":"Larrayoz","year":"2023","journal-title":"Nat Med"},{"issue":"11","key":"2024052418405094400_bib37","doi-asserted-by":"crossref","first-page":"1351","DOI":"10.1038\/nm.4202","article-title":"Microenvironment-dependent growth of preneoplastic and malignant plasma cells in humanized mice","volume":"22","author":"Das","year":"2016","journal-title":"Nat Med"},{"issue":"6","key":"2024052418405094400_bib38","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1038\/s41590-021-00931-3","article-title":"The multiple myeloma microenvironment is defined by an inflammatory stromal cell landscape","volume":"22","author":"de Jong","year":"2021","journal-title":"Nat Immunol"},{"issue":"4","key":"2024052418405094400_bib39","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1002\/eji.201445295","article-title":"Memory CD8(+) T cells colocalize with IL-7(+) stromal cells in bone marrow and rest in terms of proliferation and transcription","volume":"45","author":"Sercan Alp","year":"2015","journal-title":"Eur J Immunol"},{"issue":"10","key":"2024052418405094400_bib40","doi-asserted-by":"crossref","first-page":"3905","DOI":"10.1172\/JCI85329","article-title":"ABC transporters and NR4A1 identify a quiescent subset of tissue-resident memory T cells","volume":"126","author":"Boddupalli","year":"2016","journal-title":"J\u00a0Clin Invest"},{"issue":"19","key":"2024052418405094400_bib41","doi-asserted-by":"crossref","first-page":"4924","DOI":"10.3390\/cancers13194924","article-title":"Reference values to assess hemodilution and warn of potential false-negative minimal residual disease results in myeloma","volume":"13","author":"Puig","year":"2021","journal-title":"Cancers (Basel)"},{"issue":"2","key":"2024052418405094400_bib42","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1158\/1078-0432.CCR-19-2309","article-title":"Mutation-derived neoantigen-specific T-cell responses in multiple myeloma","volume":"26","author":"Perumal","year":"2020","journal-title":"Clin Cancer Res"},{"issue":"15","key":"2024052418405094400_bib43","doi-asserted-by":"crossref","first-page":"e167629","DOI":"10.1172\/JCI167629","article-title":"Regulation of antigen-specific T cell infiltration and spatial architecture in multiple myeloma and premalignancy","volume":"133","author":"Robinson","year":"2023","journal-title":"J\u00a0Clin Invest"},{"issue":"1","key":"2024052418405094400_bib44","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1038\/s41375-019-0519-4","article-title":"Dynamic CD138 surface expression regulates switch between myeloma growth and dissemination","volume":"34","author":"Akhmetzyanova","year":"2020","journal-title":"Leukemia"},{"issue":"6","key":"2024052418405094400_bib45","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1111\/bjh.12708","article-title":"Immunomodulatory agents lenalidomide and pomalidomide co-stimulate T cells by inducing degradation of T cell repressors Ikaros and Aiolos via modulation of the E3 ubiquitin ligase complex CRL4(CRBN.)","volume":"164","author":"Gandhi","year":"2014","journal-title":"Br J Haematol"},{"issue":"5","key":"2024052418405094400_bib46","doi-asserted-by":"crossref","first-page":"1787","DOI":"10.1182\/blood-2003-02-0361","article-title":"Immunomodulatory drug costimulates T cells via the B7-CD28 pathway","volume":"103","author":"LeBlanc","year":"2004","journal-title":"Blood"},{"issue":"2","key":"2024052418405094400_bib47","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1182\/blood-2005-10-4184","article-title":"Enhancement of ligand dependent activation of human natural killer T cells by Lenalidomide: therapeutic implications","volume":"108","author":"Chang","year":"2006","journal-title":"Blood"},{"issue":"26","key":"2024052418405094400_bib48","doi-asserted-by":"crossref","first-page":"4042","DOI":"10.1182\/blood-2014-11-611426","article-title":"Clinical and pharmacodynamic analysis of pomalidomide dosing strategies in myeloma: impact of immune activation and cereblon targets","volume":"125","author":"Sehgal","year":"2015","journal-title":"Blood"},{"issue":"11","key":"2024052418405094400_bib49","doi-asserted-by":"crossref","first-page":"4839","DOI":"10.1182\/blood-2006-10-054221","article-title":"Bortezomib enhances dendritic cell (DC) mediated induction of immunity to human myeloma via exposure of cell surface heat shock protein 90 on dying tumor cells: therapeutic implications","volume":"109","author":"Spisek","year":"2007","journal-title":"Blood"},{"issue":"5","key":"2024052418405094400_bib50","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1158\/2643-3230.BCD-21-0047","article-title":"Bortezomib induces anti-multiple myeloma immune response mediated by cGAS\/STING pathway activation","volume":"2","author":"Gulla","year":"2021","journal-title":"Blood Cancer Discov"},{"issue":"3","key":"2024052418405094400_bib51","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1182\/blood-2015-12-687749","article-title":"Daratumumab depletes CD38+ immune regulatory cells, promotes T-cell expansion, and skews T-cell repertoire in multiple myeloma","volume":"128","author":"Krejcik","year":"2016","journal-title":"Blood"},{"issue":"10","key":"2024052418405094400_bib52","doi-asserted-by":"crossref","first-page":"1941","DOI":"10.1158\/1535-7163.MCT-21-0035","article-title":"Belantamab mafodotin (GSK2857916) drives immunogenic cell death and immune-mediated antitumor responses in\u00a0vivo","volume":"20","author":"Montes de Oca","year":"2021","journal-title":"Mol Cancer Ther"},{"issue":"1","key":"2024052418405094400_bib53","doi-asserted-by":"crossref","first-page":"5335","DOI":"10.1038\/s41467-023-40966-8","article-title":"Immunophenotypic correlates of sustained MRD negativity in patients with multiple myeloma","volume":"14","author":"Coffey","year":"2023","journal-title":"Nat Commun"},{"issue":"2","key":"2024052418405094400_bib54","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1158\/2643-3230.BCD-22-0173","article-title":"Impaired SARS-CoV-2 variant neutralization and CD8+ T-cell responses following 3 doses of mRNA vaccines in myeloma: correlation with breakthrough infections","volume":"4","author":"Azeem","year":"2023","journal-title":"Blood Cancer Discov"},{"issue":"26","key":"2024052418405094400_bib55","doi-asserted-by":"crossref","first-page":"3057","DOI":"10.1200\/JCO.21.02257","article-title":"Determinants of neutralizing antibody response after SARS CoV-2 vaccination in patients with myeloma","volume":"40","author":"Nooka","year":"2022","journal-title":"J Clin Oncol"},{"issue":"9","key":"2024052418405094400_bib56","doi-asserted-by":"crossref","first-page":"2286","DOI":"10.1038\/s41591-023-02496-0","article-title":"Idecabtagene vicleucel for relapsed and refractory multiple myeloma: post hoc 18-month follow-up of a phase 1 trial","volume":"29","author":"Lin","year":"2023","journal-title":"Nat Med"},{"issue":"Supplement 1","key":"2024052418405094400_bib57","doi-asserted-by":"crossref","first-page":"2099","DOI":"10.1182\/blood-2023-182298","article-title":"Biomarker correlates of response to ciltacabtagene autoleucel in patients with relapsed or refractory multiple myeloma from CARTITUDE-1, a phase 1b\/2 open-label study, at the \u223c3 year follow-up","volume":"142","author":"Montes de Oca","year":"2023","journal-title":"Blood"},{"issue":"19","key":"2024052418405094400_bib58","doi-asserted-by":"crossref","first-page":"2812","DOI":"10.1182\/bloodadvances.2019000600","article-title":"T-cell phenotypes associated with effective CAR T-cell therapy in postinduction vs relapsed multiple myeloma","volume":"3","author":"Garfall","year":"2019","journal-title":"Blood Adv"},{"issue":"4","key":"2024052418405094400_bib59","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1016\/j.ccell.2023.02.008","article-title":"The pre-existing T cell landscape determines the response to bispecific T cell engagers in multiple myeloma patients","volume":"41","author":"Friedrich","year":"2023","journal-title":"Cancer Cell"},{"issue":"S2","key":"2024052418405094400_bib60","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1097\/01.HS9.0000936256.84340.a7","article-title":"P32 Majestec-1: correlative analyses of teclistamab, a B-cell maturation antigen (BCMA) X CD3 bispecific antibody, in patients with relapsed\/refractory multiple myeloma (RRMM)","volume":"7","author":"van de Donk","year":"2023","journal-title":"Hemasphere"},{"issue":"7","key":"2024052418405094400_bib61","doi-asserted-by":"crossref","first-page":"1600","DOI":"10.1182\/bloodadvances.2023011225","article-title":"CD8 effector T cells enhance response in BCMA-exposed and -naive multiple myeloma","volume":"8","author":"Firestone","year":"2024","journal-title":"Blood Adv"},{"issue":"5","key":"2024052418405094400_bib62","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1158\/2643-3230.BCD-21-0028","article-title":"Bispecific antibodies in multiple myeloma: present and future","volume":"2","author":"Lancman","year":"2021","journal-title":"Blood Cancer Discov"},{"issue":"12","key":"2024052418405094400_bib63","doi-asserted-by":"crossref","first-page":"e183267","DOI":"10.1001\/jamaoncol.2018.3267","article-title":"Assessment of safety and immunogenicity of PVX-410 vaccine with or without lenalidomide in patients with smoldering multiple myeloma: a nonrandomized clinical trial","volume":"4","author":"Nooka","year":"2018","journal-title":"JAMA Oncol"},{"issue":"23","key":"2024052418405094400_bib64","doi-asserted-by":"crossref","first-page":"4784","DOI":"10.1158\/1078-0432.CCR-23-0235","article-title":"Randomized phase II trial of dendritic cell\/myeloma fusion vaccine with lenalidomide maintenance after upfront autologous hematopoietic cell transplantation for multiple myeloma: BMT CTN 1401","volume":"29","author":"Chung","year":"2023","journal-title":"Clin Cancer Res"},{"issue":"22","key":"2024052418405094400_bib65","doi-asserted-by":"crossref","first-page":"4575","DOI":"10.1158\/1078-0432.CCR-22-3987","article-title":"Survivin dendritic cell vaccine safely induces immune responses and is associated with durable disease control after autologous transplant in patients with myeloma","volume":"29","author":"Freeman","year":"2023","journal-title":"Clin Cancer Res"},{"issue":"9","key":"2024052418405094400_bib66","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.1182\/blood.2020008493","article-title":"A\u00a0randomized phase 2 trial of idiotype vaccination and adoptive autologous T-cell transfer in patients with multiple myeloma","volume":"139","author":"Qazilbash","year":"2022","journal-title":"Blood"},{"issue":"3","key":"2024052418405094400_bib67","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1182\/blood-2012-06-435503","article-title":"Clinical regressions and broad immune activation following combination therapy targeting human NKT cells in myeloma","volume":"121","author":"Richter","year":"2013","journal-title":"Blood"},{"issue":"22","key":"2024052418405094400_bib68","doi-asserted-by":"crossref","first-page":"4524","DOI":"10.1158\/1078-0432.CCR-23-2292","article-title":"Harnessing dendritic cells: next frontier for durable immune control in myeloma","volume":"29","author":"Dhodapkar","year":"2023","journal-title":"Clin Cancer Res"},{"issue":"1","key":"2024052418405094400_bib69","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1038\/s41467-017-00296-y","article-title":"Spatial genomic heterogeneity in multiple myeloma revealed by multi-region sequencing","volume":"8","author":"Rasche","year":"2017","journal-title":"Nat Commun"},{"issue":"1","key":"2024052418405094400_bib70","doi-asserted-by":"crossref","first-page":"5011","DOI":"10.1038\/s41467-023-40584-4","article-title":"Resolving the spatial architecture of myeloma and its microenvironment at the single-cell level","volume":"14","author":"John","year":"2023","journal-title":"Nat Commun"},{"issue":"11","key":"2024052418405094400_bib71","doi-asserted-by":"crossref","first-page":"1403","DOI":"10.1001\/jamaoncol.2016.2450","article-title":"Classification of advanced human cancers based on tumor immunity in the microenvironment (TIME) for cancer immunotherapy","volume":"2","author":"Zhang","year":"2016","journal-title":"JAMA Oncol"},{"issue":"1","key":"2024052418405094400_bib72","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1186\/s12943-024-01941-z","article-title":"Mapping cancer biology in space: applications and perspectives on spatial omics for oncology","volume":"23","author":"Lee","year":"2024","journal-title":"Mol Cancer"},{"issue":"3","key":"2024052418405094400_bib73","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1038\/s41590-024-01768-2","article-title":"Integrating single-cell multi-omics and prior biological knowledge for a functional characterization of the immune system","volume":"25","author":"Schafer","year":"2024","journal-title":"Nat Immunol"},{"issue":"1","key":"2024052418405094400_bib74","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/j.immuni.2019.12.018","article-title":"Tumor immunology and tumor evolution: intertwined histories","volume":"52","author":"Galon","year":"2020","journal-title":"Immunity"},{"issue":"3","key":"2024052418405094400_bib75","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1016\/j.cell.2018.09.018","article-title":"Evolution of metastases in space and time under immune selection","volume":"175","author":"Angelova","year":"2018","journal-title":"Cell"},{"issue":"9","key":"2024052418405094400_bib76","doi-asserted-by":"crossref","first-page":"2295","DOI":"10.1038\/s41591-023-02491-5","article-title":"Mechanisms of antigen escape from BCMA- or GPRC5D-targeted immunotherapies in multiple myeloma","volume":"29","author":"Lee","year":"2023","journal-title":"Nat Med"},{"issue":"5","key":"2024052418405094400_bib77","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1158\/2643-3230.BCD-23-0044","article-title":"Time-dependent prognostic value of serological and measurable residual disease assessments after idecabtagene vicleucel","volume":"4","author":"Paiva","year":"2023","journal-title":"Blood Cancer Discov"},{"issue":"11","key":"2024052418405094400_bib78","doi-asserted-by":"crossref","first-page":"2087","DOI":"10.1200\/JCO.22.01365","article-title":"Idecabtagene vicleucel for relapsed\/refractory multiple myeloma: real-world experience from the myeloma CAR T consortium","volume":"41","author":"Hansen","year":"2023","journal-title":"J\u00a0Clin Oncol"},{"issue":"1","key":"2024052418405094400_bib79","doi-asserted-by":"crossref","first-page":"868","DOI":"10.1038\/s41467-021-21177-5","article-title":"Biallelic loss of BCMA as a resistance mechanism to CAR T cell therapy in a patient with multiple myeloma","volume":"12","author":"Samur","year":"2021","journal-title":"Nat Commun"},{"issue":"19","key":"2024052418405094400_bib80","doi-asserted-by":"crossref","first-page":"3794","DOI":"10.1182\/bloodadvances.2021004418","article-title":"Single- and double-hit events in genes encoding immune targets before and after T cell-engaging antibody therapy in MM","volume":"5","author":"Truger","year":"2021","journal-title":"Blood Adv"},{"key":"2024052418405094400_bib81","doi-asserted-by":"crossref","first-page":"102329","DOI":"10.1016\/j.coi.2023.102329","article-title":"Tumor immune evasion through loss of MHC class-I antigen presentation","volume":"83","author":"Sari","year":"2023","journal-title":"Curr Opin Immunol"},{"issue":"4","key":"2024052418405094400_bib82","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1038\/s41591-021-01245-5","article-title":"Homozygous BCMA gene deletion in response to anti-BCMA CAR T cells in a patient with multiple myeloma","volume":"27","author":"Da Via","year":"2021","journal-title":"Nat Med"},{"issue":"11","key":"2024052418405094400_bib83","doi-asserted-by":"crossref","first-page":"1536","DOI":"10.1038\/s43018-023-00625-9","article-title":"Acquired resistance to a GPRC5D-directed T-cell engager in multiple myeloma is mediated by genetic or epigenetic target inactivation","volume":"4","author":"Derrien","year":"2023","journal-title":"Nat Cancer"},{"issue":"3","key":"2024052418405094400_bib84","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1038\/nrc.2017.117","article-title":"Impact of oncogenic pathways on evasion of antitumour immune responses","volume":"18","author":"Spranger","year":"2018","journal-title":"Nat Rev Cancer"},{"issue":"1","key":"2024052418405094400_bib85","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1186\/s40164-023-00436-9","article-title":"Bispecific antibodies and dual-targeting CAR-T cells for multiple myeloma: latest updates from the 2023 ASCO annual meeting","volume":"12","author":"Hou","year":"2023","journal-title":"Exp Hematol Oncol"},{"issue":"5","key":"2024052418405094400_bib86","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.1016\/j.cell.2018.01.004","article-title":"NK cells stimulate recruitment of cDC1 into the tumor microenvironment promoting cancer immune control","volume":"172","author":"Bottcher","year":"2018","journal-title":"Cell"},{"issue":"12","key":"2024052418405094400_bib87","first-page":"670","article-title":"Advances in the development of vaccines and other immunotherapies for multiple myeloma","volume":"17","author":"Avigan","year":"2019","journal-title":"Clin Adv Hematol Oncol"},{"issue":"12","key":"2024052418405094400_bib88","doi-asserted-by":"crossref","first-page":"1411","DOI":"10.1038\/nm.4229","article-title":"IAP antagonists induce anti-tumor immunity in multiple myeloma","volume":"22","author":"Chesi","year":"2016","journal-title":"Nat Med"},{"issue":"3","key":"2024052418405094400_bib89","doi-asserted-by":"crossref","first-page":"e41","DOI":"10.1111\/bjh.15888","article-title":"Phase 1b trial of pembrolizumab monotherapy for relapsed\/refractory multiple myeloma: KEYNOTE-013","volume":"186","author":"Ribrag","year":"2019","journal-title":"Br J Haematol"},{"issue":"4","key":"2024052418405094400_bib90","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1158\/2643-3230.BCD-21-0038","article-title":"Tumor burden limits bispecific antibody efficacy through T cell exhaustion averted by concurrent cytotoxic therapy","volume":"2","author":"Meermeier","year":"2021","journal-title":"Blood Cancer Discov"},{"issue":"12","key":"2024052418405094400_bib91","doi-asserted-by":"crossref","first-page":"2598","DOI":"10.1158\/1078-0432.CCR-21-3430","article-title":"A\u00a0machine learning model based on tumor and immune biomarkers to predict undetectable MRD and survival outcomes in multiple myeloma","volume":"28","author":"Guerrero","year":"2022","journal-title":"Clin Cancer Res"}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/8\/10\/2424\/2226437\/blooda_adv-2023-011242-c-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/8\/10\/2424\/2226437\/blooda_adv-2023-011242-c-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,24]],"date-time":"2024-05-24T18:41:30Z","timestamp":1716576090000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/8\/10\/2424\/515575\/Immune-status-and-selection-of-patients-for"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5,20]]},"references-count":91,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2024,5,28]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2023011242","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,5,20]]}}}